Clinical trials: Thromboembolic Disorders
Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Vasopressor Agents in Pulmonary Hypertension Crisis
Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Hypertension, Pulmonary
- Trial name
- NCT07667829
- Testing
- Norepinephrine, Dopamine, Epinephrine
- Where
- 3 sites in China
- Volunteers
- 75 people
- Sponsor
- China National Center for Cardiovascular Diseases
Chronic Thromboembolic Pulmonary Hypertension
Early Non-invasive Detection of CTEPH After Pulmonary Embolism
This is a prospective, international, multicenter outcome cohort study. This study starts at the moment patients visit the outpatient clinic 3 to 6 months after a diagnosis of acute PE as part of routine medical care.
- Trial name
- InShape2 (NCT02555137)
- Testing
- 'prediction score' and 'rule-out criteria'
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 424 people
- Sponsor
- Leiden University
Chronic Thromboembolic Pulmonary Hypertension
Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension
Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH) is a rare but severe complication of pulmonary embolism (PE). CTEPH is evoked in patients with persistent dyspnea.
- Trial name
- PROTEO-CTEPH (NCT05340023)
- Testing
- blood sample
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Atrial Fibrillation (AF)
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF).
- Trial name
- DESTINATION (NCT06615596)
- Testing
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Where
- 12 sites in United States, China
- Volunteers
- 3,160 people
- Sponsor
- China National Center for Cardiovascular Diseases
Chronic Thromboembolic Pulmonary Hypertension
Identification of Criteria of the Success of the Endarterectomy in Chronic Pulmonary Post Embolic Hypertension
In order to improve effectiveness of the surgical operation thanks to a reduction in the rate of failure, this study will allow us to identify predictive angiographic and CT finding of surgical failure, starting from standardized…
- Trial name
- ETHAPE (NCT00657722)
- Testing
- Angiography and Computed Tomography
- Where
- 2 sites in France
- Volunteers
- 249 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)
The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary…
- Conditions
- Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07777445
- Testing
- 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Silvia Ulrich Somaini
Polycythemia Vera
Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis.
- Trial name
- Prospero (NCT05548062)
- Testing
- Hydroxyurea, Ruxolitinib
- Where
- 33 sites in Italy
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
RATIONALE: Dalteparin may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028678
- Testing
- dalteparin, radiation therapy
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Eastern Cooperative Oncology Group
Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
The objective of the present study is to assess blood coagulation disorders in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.
- Trial name
- NCT03195543
- Testing
- Platelet function analyzer-100, Light transmission aggregometry, Rotational thromboelastometry
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Covid-19, Thromboembolic Events
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission…
- Conditions
- Covid-19, Thromboembolic Events, Bleeding
- Trial name
- NCT04412304
- Testing
- Dose of Tinzaparin or Dalteparin
- Where
- Sweden
- Volunteers
- 166 people
- Sponsor
- Karolinska Institutet
Intracranial Embolism
Electrical Cardioversion of Recent Onset Atrial Fibrillation - Silent Thromboembolic Events, Reverse Atrial Remodeling
The purpose of this study is to study the effects of transthoracic electrical cardioversion for restoration of sinus rhythm in patients who present with recent onset atrial fibrillation, with regard to new silent cerebral…
- Trial name
- ECAF-STAR (NCT02955004)
- Testing
- Electrical cardioversion
- Where
- 3 sites in Sweden
- Volunteers
- 43 people
- Sponsor
- Uppsala University Hospital
Atrial Fibrillation
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
Evaluate efficacy and safety of Indobufen v. Aspirin in preventing thromboembolic events in patients at high risk of CV events such as patients suffering from nonrheumatic atrial fibrillation.
- Trial name
- SIFA (NCT00244426)
- Testing
- indobufen, aspirin
- Where
- 132 sites in Italy
- Volunteers
- 1,372 people
- Sponsor
- Pfizer
Thromboembolic Venous Disease
Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence
The main objective of the BREIZH-Cohorte study is to determine the incidence of recurrent short, medium and long-term thromboembolic venous disease as well as risk factors for recurrence in two specific populations: patients…
- Trial name
- BREIZH-Cohorte (NCT04297085)
- Testing
- Biologic sample
- Where
- 4 sites in France
- Volunteers
- 3,400 people
- Sponsor
- University Hospital, Brest
Prevention of Thromboembolic Events, Atrial Fibrillation
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
This is an observational study in which data from people with atrial fibrillation who received or are currently receiving the drug apixaban to prevent thromboembolic events (blood clots that travel through the blood stream to…
- Trial name
- NCT05471830
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation therapy with a lower risk of bleeding in…
- Trial name
- NCT00243178
- Testing
- clopidogrel (SR25990C)
- Where
- 32 sites in United States, Australia and 30 more
- Volunteers
- 6,706 people
- Sponsor
- Sanofi
Atrial Fibrillation, Thromboembolism
Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk
The purpose of this study is to investigate the appropriate duration of dabigatran use after radiofrequency catheter ablation for paroxysmal atrial fibrillation in patients with low thromboembolic risk.
- Trial name
- NCT02313584
- Testing
- dabigatran
- Volunteers
- 464 people
- Sponsor
- Korea University
Venous Thromboembolic Disease
Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy
The Quantra(r) hemostasis analyzer (Stago) is a recent addition to the family of global hemostasis tests. It uses ultrasound-based technology to characterize the viscoelastic properties of a whole blood sample during coagulation.
- Trial name
- QuantiXa (NCT05993533)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Venous Thromboembolism, Hypercholesterolemia
Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis
Elevated levels of D-dimer, a marker of procoagulant state, have been identified as a marker of an increased risk of recurrent VTE.
- Trial name
- NCT00437892
- Testing
- atorvastatin, diet
- Where
- 3 sites in Italy
- Volunteers
- 10 people
- Sponsor
- Università degli Studi dell'Insubria
Venous Thromboembolic Diseases
Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum
The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.
- Trial name
- NCT01588171
- Testing
- Bemiparin, Enoxaparin
- Where
- Iraq
- Volunteers
- 7,020 people
- Sponsor
- Hawler Medical University
Thrombosis, Cancer
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic…
- Conditions
- Thrombosis, Cancer, Pulmonary Embolism
- Trial name
- NCT00320255
- Testing
- Apixaban
- Where
- 14 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Bristol-Myers Squibb